Earnings Call · Q4 FY2023·2024-02-28

Q4 23EPS +100.00%*·Rev n/aQ3 23EPS -25.00%·Rev n/aQ2 23EPS +100.00%*·Rev n/aQ1 23EPS +14.29%·Rev n/a⚠ consensus missing

Kiniksa Pharmaceuticals International, plc KNSA

Rachel Frank — Investor Relations

Sanj Patel — Chief Executive Officer

Ross Moat — Chief Commercial Officer

John Paolini — Chief Medical Officer

Mark Ragosa — Chief Financial Officer

−2.5%1d on move date−2.4% vs SPY3d+4.1%5d−3.4%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more KNSA calls or request research access.

More KNSA calls Browse calls Request research access